SWI/SNF subunit BAF155 N-terminus structure informs the impact of cancer-associated mutations and reveals a potential drug binding site by Allen, Mark D. et al.
ARTICLE
SWI/SNF subunit BAF155 N-terminus structure
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SWI/SNF (BAF) chromatin remodelling complexes are key regulators of gene expression
programs, and attractive drug targets for cancer therapies. Here we show that the N-terminus
of the BAF155/SMARCC1 subunit contains a putative DNA-binding MarR-like domain, a
chromodomain and a BRCT domain that are interconnected to each other to form a distinct
module. In this structure the chromodomain makes interdomain interactions and has lost its
canonical function to bind to methylated lysines. The structure provides new insights into the
missense mutations that target this module in cancer. This study also reveals two adjacent,
highly-conserved pockets in a cleft between the domains that form a potential binding site,
which can be targeted with small molecules, offering a new strategy to target SWI/SNF
complexes.
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mSWI/SNF or BAF complexes are ATP-dependent chro-matin regulators1. They are combinatorially assembledfrom 16 subunits encoded by 31 genes into a range of
complexes with specific and distinct roles in many key biological
processes. Several of the subunits are frequently mutated in a
range of cancers. mSWI/SNF complexes have a role in both
tumour suppression and oncogenesis, and have emerged as pro-
mising targets for cancer therapy1,2. The development of small
molecules targeting these complexes remains challenging as many
of the subunits lack amenable binding sites. The BAF155/
SMARCC1 subunit is a component of all complexes identified to
date, incorporated either as a homodimer or as a heterodimer
with its paralog BAF170/SMARCC2. The BAF155 subunit pre-
dominates in stem cells, while the BAF170 subunit is incorpo-
rated during differentiation. BAF155 is the only subunit present
in the esBAF and ncBAF complexes3. BAF155 is a potential
therapeutic target for colorectal4 and prostate5 cancers. Both
BAF155 and BAF170 are mutated in several cancers with the
worst prognosis, for which no therapies are available. It has been
found that cells with mutations in either of the subunits are
sensitive to the loss of the other paralog, providing a means of
selectively targeting cancers in which these subunits are mutated6.
This type of synthetic lethal interaction has been exploited to
target cancers in which the SMARCA4 subunit is mutated by
employing PROTAC degraders directed at its paralog
SMARCA27.
Only 27% of the residues of BAF155 are visible in the recent
cryo-EM structure of the BAF complex8,9 (Fig. 1a). These amino
acids make extensive contacts with other subunits and offer no
targetable binding sites. The rest of the protein is predicted to be
intrinsically disordered with the exception of an approximately
250-amino-acid region at the N-terminus (Fig. 1a), which, based
on sequence analysis, is expected to contain a chromodomain and
a BRCT domain, uniquely having the former in the middle of the
latter. No cross-linking between this region and any other BAF
subunit has been detected in several proteomics studies. This is
similar to what has been observed for the bromodomain of the
SMARCA4 subunit and the PHD finger domains of the
Dpf2 subunit, both of which mediate interactions with
chromatin9. Although BAF155 homologues are ubiquitous in
eukaryotes, this region is only found in metazoa. The presence of
the N-terminal module in these species suggests that its acquisi-
tion is linked to more-complex regulation of gene expression in
multicellular animals, however, nothing is known about its
function. Chromodomains can recognize methylated lysine resi-
dues in histones, and BRCT domains are found in many proteins
that participate in the DNA damage response, suggesting that this
region could play an important role in regulating the activity of
the complex. Both of these domains are also being explored as
potential small-molecule targets for drug discovery.
We therefore set out to determine the structure of the N-
terminus of BAF155 using X-ray crystallography. This shows that
the this region contains a distinct structural module where the
chromodomain, the BRCT domain and a MarR-like domain are
interconnected by a complex hydrogen-bond network. This
also reveals the presence of a binding pocket at the interface
between the three domains that can be targeted by a small-
molecule drug. The structure of the N-terminus allows the
assessment of the impact of mutations in cancer that target
BAF155 and its paralogue BAF170. This study offers a potential
approach to develop cancer therapies.
Results and discussion
Overall structure and architectural organization of BAF155 N-
terminus. Residues 27–383 of BAF155 were expressed and
purified, and their structure determined using X-ray crystal-
lography (Fig. 1b, Supplementary Fig. 1a and Table 1). Residues
4–160 form a four-helix-bundle that resembles the MarR-like
helix-turn-helix domain10 based on structure homology analysis
using VAST:11 43 aligned residues, RMSD for CA atoms of 1.9,
score 5.1, P-value= 0.0005 for the highest scoring protein (Sup-
plementary Fig. 2a). Interestingly, a homologous domain is also
present in the INI1/SNF5/SMARCB1 subunit12. MarR domains
bind to the major groove of DNA via the second helix of the motif
with a β-strand wing also contacting the minor groove (Fig. 1c).
The wing is absent in our structure, but residues in α2 are highly
conserved as are residues in the adjacent loop between α3 and α4.
Both α1 and α4 are longer than in MarR domains and the
orientation of α4 differs to allow for interactions with other
domains in the module (Fig. 1b). This would block the type of
interaction that MarR domains normally make with DNA,
although the BAF155 module could interact with distorted DNA
structures. Residues 169–287 consist of a BRCT domain with a
chromodomain (residues 219–246) inserted between the second
and third strands of the canonical fold (Supplementary Fig. 1a).
Helix 2 that forms part of a phosphate-binding site in many
BRCT domains13 is missing (Supplementary Fig. 2). The chro-
modomain consists of the curved antiparallel three-stranded β-
sheet characteristic of this domain. The C-terminal helix that
packs across the β-sheet14 in many chromodomains is not present
in the BAF155 structure; instead hydrophobic residues (Val249,
Ile253) in the loop, which links the chromodomain to β2 of the
BRCT domain pack onto the sheet (Fig. 1d).
The individual domains are linked via a network of hydrogen
bonds to form a single structural unit in which a highly conserved
stretch of amino acids in the α3-α4 loop and α4 of the BRCT
domain plays a central role (Fig. 1d). The sidechain of Asn277
hydrogen bonds to residues in the α2-α3 loop of the MarR-like
domain. These domains are also linked by hydrogen bonding
between Glu156 in α4 of the MarR-like domain and Glu192 at the
C-terminus of α1 of the BRCT domain. The sidechain of Glu278
hydrogen bonds to the sidechain and backbone of Ser239 in the
small helix between β2 and β3 of the chromodomain. The
sidechain of Ser239 also hydrogen bonds to the sidechain of
Lys103 linking the chromodomain to the MarR-like domain.
Asp284 hydrogen bonds to the sidechains of Arg220 at the start
of β1 and His232 at the end of β2 of the chromodomain and the
amide of Phe235 in the β2-α1 loop. The BRCT domain is
followed by a hairpin turn allowing Arg297 to form a salt bridge
with Glu283. The backbone amides of residues Thr300 and
Ile302, which are located at the C-terminus of the module,
hydrogen bond with the backbone carbonyls of Glu217 and
Leu219 at the start of β1 of the chromodomain. Analysis of the
sequence of human chromodomains shows that the BAF155
domain clusters with so-called “chromobarrel domains”14. This
sub family of chromodomains have an additional N-terminal
strand that precedes the chromodomain fold: the BAF155
chromodomain does have a chromobarrel fold, but in this case
the residues located at the C-terminus of the module form the
additional strand. Residues 28–33 pack onto the chromodomain,
and a main-chain to main-chain hydrogen bond is formed
between Leu28 and Ile300 linking the N- and C-termini of the
module.
A non-functional chromodomain. The N-terminal residues
interact with a region of the chromodomain that in others forms
an aromatic cage that binds to methylated lysines. Only two of the
three residues of the cage, in for example CBX7, are present
(Trp233, Tyr236) in the BAF155 chromodomain (Supplementary
Fig. 3a), and Arg32 is positioned where the methylated lysine
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sidechain would interact14 (Fig. 1e). As is the case for other
chromobarrel domains, the presence of the additional strand
prevents the domain from making the types of interaction that
polycomb or HP1 family chromodomains make with the residues
adjacent to methylated lysines in histone H3. Chromobarrel
domains that interact with methylated lysine, such as the MSL3
domain, only contact the modification, without making sig-
nificant contact with the adjacent amino-acid residues. Therefore,
for these types of domain, free methylated lysine has been used15
to probe their ability to interact with histone modifications. No
binding to free methylysine derivatives (mono-, di- or tri-
methylated) to the BAF155 chromodomain was detected using
NMR spectroscopy, which has been used to characterize even
very weak binding to aromatic cages15 (Supplementary Fig. 3b, c).
This is not unprecedented as many other chromobarrel domains
also do not interact with methylated histones. The domain from
TIP60, for example, which is closely related in terms of sequence
to the BAF155 chromodomain, lacks the same residue in the
aromatic cage, and also has an Arginine residue inserted where
the methylated lysine would normally bind16 (Supplementary
Fig. 3d).
Identification of a binding pocket at the interface between the
three domains. The architecture of the fold produces a cleft
containing two deep pockets at the interface between the
Fig. 1 X-ray structure of the N-terminal module of BAF155. a Domain organization of BAF155. Blue bars indicate regions visible in the cryo-EM structure
(6LTH). b Cartoon representation of the structure with BRCT domain in cyan, chromodomain in blue, the MarR-like domain in green. c Overlay of the
carton representations of the MarR-like domain structure (in green) of BAF155 and of the protein TipAL (in purple, bound to DNA in orange, PBD ID=
2VZ4). d Zoom in of the hydrogen-bonding network. Residues in the hydrogen-bonding network are shown in stick representation for the three domains
and the C- and the N-termini (pink= BRCT domain, yellow= chromodomain, purple=MarR-like domain). e Overlay of the cartoon representation of the
chromodomains of BAF155 (in blue) and CBX7 (PDB ID= 4X3K) (in grey). Residues of the aromatic cage are shown in yellow in BAF155 and in pink in
CBX7, illustrating the blocking of the methyl-lysine-binding site on BAF155 by Arg32 (in purple).
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domains. Analysis of the sequence conservation using ConSurf17
(Fig. 2 and Supplementary Fig. 1a) reveals two highly conserved
regions on the surface of the module: the first on the MarR-like
domain (Supplementary Fig. 1b) and the second within this cleft.
In contrast, the two regions corresponding to the canonical
binding sites of chromodomains and BRCT domains are not
conserved (Fig. 2 and Supplementary Fig. 1a). Some of the con-
served residues in the cleft are part of the network of residues that
link the domains, while others such as Asp111 and Asp241 have
no structural role, suggesting that this region is functionally
important.
Computational analysis using PeptiMap18 predicts that the
pockets within this cleft could bind to peptides (Supplementary
Fig. 4), suggesting that this region mediates protein–protein
interactions (PPIs). As the cleft is adjacent to the conserved
region on the MarR-like domain, it is possible that N-terminal
module of BAF155 participates in an interaction involving both
protein and nucleic acid components.
Analysis of the impact of cancer-associated mutations. With the
structure in hand we examined sequence variants within the
module that have been identified in cancer-genome sequencing
studies to try and distinguish between driver and passenger
mutations. Six missense mutations of BAF155 identified in
patient samples that map to the module are predicted to desta-
bilise its structure as judged by Missense3D19 (Supplementary
Table 1). Three of these are of residues (Asp284 and Glu156) that
form salt bridges in the hydrogen-bonding network linking the
domains together. Three mutations are of highly conserved sur-
face residues (K129T, W134L and R144Q) located in the MarR-
like domain (Fig. 3a and Supplementary Fig. 1b), which are likely
to affect the function of the N-terminal module (Fig. 3a and
Supplementary Fig. 1b). As the N-terminal module is also present
in the BAF170 paralogue with 66% identity, we used our structure
to generate a homology model and carried out the same analysis
(Supplementary Table 2). In BAF170, 14 mutations are predicted
to be damaging to the fold. As seen for BAF155, several of these
are of residues in the hydrogen-bond network linking the
domains together (Fig. 3b). Eleven mutations affecting highly
conserved surface residues were identified and, like for BAF155,
the majority of these are in the MarR-like domain (Fig. 3b). The
argument that the N-terminal module is functionally important
and these mutations are tumour-promoting is reinforced by the
results of a study modelling cancer-driver events that identified a
variant in the MarR-like domain of BAF15520.
Overall, for BAF155, 14% of the mutants in the databases are
predicted to be deleterious/cancer-driver mutants, while for
BAF170 it is 38.5%. It is interesting to note that there are almost
three times more predicted driver mutants in BAF170 that is
expressed upon differentiation than in BAF155, which is found in
complexes that are known to drive proliferation.
A potential site on BAF155 for small-molecule drugs targeting.
Attempts to target BAF155 have been stymied to date by a lack of
small-molecule-binding sites. The programs Schrodinger
SiteMap21 and DoGSiteScorer22 both identify the cleft between
the domains as an amenable pocket for small-molecule binding
Fig. 2 Conservation analysis. Surface representation of the X-ray structure of the N-terminal module of BAF155 coloured by sequence conservation using
the program ConSurf.
Table 1 Data collection, phasing and refinement statistics for
SAD (SeMet) structure determination.
6YXP (Native)a 6YXO (SeMet)a
Data collection
Space group P21 P21
Cell dimensions




α, β, γ (°) 90.0, 110.311, 90.0 90.0, 110.516, 90.0





Rsym or Rmergeb 0.053 (0.611) 0.069 (0.432)
I/σI b,c 99.1 (98.2) 10.9 (2.9)
CC(1/2)b,d 0.999 (0.850) 0.997 (0.899)




Redundancyb,e 6.8 (6.9) 5.4 (5.6)
Anomalous redundancyb,e 2.8 (2.8)
Refinement
Resolution (Å) 1.60 2.00
No. of reflections 82,268 41,388








Bond lengths (Å) 0.006 0.006
Bond angles (°) 0.800 0.628
aOne crystal for each structure. bValues in parentheses are for highest resolution shell. cSignal to
noise ratio of intensities. dCC1/2 is the correlation coefficient of the mean intensities between two
random half-datasets. eMultiplicity for unique reflections. f5% of reflections were randomly selected
for determination of the free R factor, prior to any refinement. gTemperature factors averaged for all
atoms. hR.M.S. deviations from ideal geometry for bond lengths and restraint angles.
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(Fig. 4a, b): SiteMap DScore of 0.98 and DoGSiteScorer Drug
Score of 0.81.
Sites at domain–domain interfaces amenable for small-
molecule binding have been identified in other epigenetic
regulators23, and it has been suggested that they could be
exploited when so-called “epigenetic readers domains” are not
themselves suitable for ligand binding. The site has a reasonable
size and very good enclosure comparable to drug-binding sites in
Fig. 3 Deleterious mutations. a Cartoon representation of the X-ray crystal structure of the N-terminal module of BF155 with residues labelled in red for
the structurally damaging mutations, and in yellow for mutations predicted to affect functionally important residues. b Mutations in BAF170 shown on a
cartoon representation of a homology model with residues highlighted as in panel (a).
Fig. 4 Computationally identified small-molecule-binding pockets as potential druggable sites. a Surface representation of the X-ray crystal structure of
the N-terminal module of BF155 with the red dots indicating the binding site identified by SiteMap. b Binding site identified by DoGSite Scorer highlighted in
pink. c Cartoon representation of the structure with the red dots indicating the binding site identified by SiteMap: the residues of the pocket on BAF155 that
differs from BAF170 are labelled and highlighted in yellow (stick representation). d Highlighted in orange are the labelled residues (stick representation) on
the carton representation of the homology model of BAF170 that differs from BAF155.
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kinases, and an acceptable hydrophilic and hydrophobic proper-
ties compared to PPI-binding sites targeted to date. The sequence
variation within this pocket between BAF155 and
BAF170 suggests that it may be possible to create paralogue-
selective molecules (Fig. 4c, d). Molecules targeting this site can
be used as chemical probes to determine its function and as
components of PROTACs to target BAF155/BAF170 mutant
cancers.
Methods
Cloning expression and purification. The DNA encoding residues 28–303 of
BAF155 was amplified from human cDNA by PCR and cloned into a vector based
on pRSETA (Invitrogen) that expresses proteins fused to the lipoyl domain of
Bacillus stearothermophilus dihydrolipoamide acetyltransferase with an N-terminal
His6-tag. The native BAF155 module was expressed in Escherichia coli C41(DE3)
in 2xTY media and induced by the addition of IPTG (1 mM final concentration).
The cells were harvested by centrifugation, disrupted by sonication and the cell
debris were removed by centrifugation at 20,000 rpm for 30 min. The protein was
purified by Ni-NTA affinity chromatography and then dialysed overnight in the
presence of TEV protease, which cleaves the BAF155 module from the lipoyl
domain. A second affinity chromatography step was carried out to remove the
lipoyl domain and the BAF155 module was further purified by gel filtration on a
Superdex 75 HR column. K-MOPS minimal media24 was used for seleno-
methionine labelling of the module. Cells were grown to an OD600 of 0.6 after
which 100 mg/l of DL-Seleno-methionine (Sigma), 100 mg/l lysine, threonine and
phenylalanine, leucine, isoleucine and valine were added as solids. IPTG (1 mM
final concentration) was then added after a further 20 min and cells were grown for
a further 16 h at 20 °C. Isotopically labelled proteins for NMR spectroscopy were
prepared by growing cells in K-MOPS minimal media containing 15NH4Cl and/or
[13C]-glucose. Seleno-methionine (SeMet) and isotopically labelled proteins were
purified as described above.
Crystallization. The protein was concentrated to 16 mg/ml and dialysed into 10
mM Tris, pH 7.0, 100 mM NaCl for crystallization. Native and SeMet BAF155 was
crystallized at 16 mg/ml by sitting-drop vapour diffusion. Several conditions yiel-
ded crystals, both for the native and SeMet-labelled proteins, with 0.2 M magne-
sium formate (pH 5.9), 20% PEG 3350 yielding the best diffracting crystals
subsequently used for data collection. The crystals were flash-frozen in liquid
nitrogen after the addition of glycerol to 20% while leaving the other components
of the mother liquor at the same concentration.
Structure solution and refinement. SeMet BAF155 crystals belonging to space
group P21 were used to obtain phase information using the I03 beamline at Dia-
mond Light Source, Oxford (UK). Data were obtained from 1800 images collected
at 0.9755 Å with 0.1° increments at 100 K/−173.5 °C (wavelength of data collection
0.975456 Å). All images were integrated using XDS25 and scaled using SCALA26.
Phases were obtained using Phaser SAD27 in the CCP4i software28 in combination
with PARROT29 and SHELXD30. The initial output was subsequently built using
BUCCANEER31 and further refined using iterative rounds of COOT32 and
PHENIX33. Two molecules of BAF155 were observed in the asymmetric unit of the
P21 SeMet SAD dataset.
Percentage of residues in the ‘most favoured region’ of the Ramachandran plot:
97.93, 0.00; and percentage of outliers (Molprobity Clash Score): 7.22.
A native dataset, containing 1800 images collected at 0.1° increments
(wavelength of data collection 0.939273 Å), was collected at beamline I03 of the
Diamond Light Source at 100 K/−173.5 °C. The structure of native BAF155
module was obtained using molecular replacement from a refined structure of the
protein obtained from the SeMet SAD data. All structures were refined using
iterative rounds of COOT32 and PHENIX33.
Percentage of residues in the ‘most favoured region’ of the Ramachandran plot:
97.94, 0.00; and percentage of outliers (Molprobity Clash Score): 5.05.
Cell constants and crystallographic data, and details of the refined models
shown in Table 1.
NMR binding studies. NMR measurements were made using a Bruker
DRX600 spectrometer equipped with a triple-resonance cryoprobe at 25 °C. NMR
samples were typically 0.5 mM in 90% H2O, 10% D2O, containing 20 mM potas-
sium phosphate, pH 6.5, 100 mM NaCl and 5 mM β-mercaptoethanol. Backbone
assignments were carried using HNCO, HN(CA)CO, HNCA, HNCACB, CBCA
(CO)HN 3D heteronuclear NMR experiments on 2H-, 13C- and 15N-labelled
samples using standard Bruker pulse programs. Topspin (Bruker) was used for data
processing and SPARKY was used for data analysis. The ability of the module to
binding to mono, di and tri methyl-lysine was assessed by recording 1H-15N HQSC
spectra of 15N-labelled protein with and without the addition of a five-fold excess
of the amino acid.
Conservation analysis. A multiple alignment of sequences of BAF155 and
BAF170 homologues from different model organisms was prepared using Clustal
Omega34. The ConSurf17 server was used to calculate conservation scores, using
default values and the Bayesian method.
Mutational analysis. Missense mutations within the N-terminal modules of
BAF155 and BAF170 were extracted from the cBioPortal35 and the COSMIC36
databases. Only mutations from tumour samples were considered. To assess the
effects of mutations in the equivalent module in BAF170 (which has 66% sequence
identity to that in BAF155) we used the BAF155 structure to generate a homology
model using the One-to-One Threading option in PHYRE237 (the resulting model
had a 100% confidence score). The program Missense3D19 was used to evaluate the
effect of mutations on the stability of the modules. Variants were judged to have an
effect on protein function if they are non-conservative substitutions of surface
residues with ConSurf scores of 8 or 9.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The coordinate of the crystal structures are deposited in the Protein Data Bank (PBD),
and the accession identifiers are 6YXO and 6YXP.
The NMR assignments are deposited in the Biological Magnetic Resonance Bank
BMRB, and the accession identifier is 50830.
All the other data are available from the corresponding author on reasonable request.
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